Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190


Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.

Kim DR, Park MY, Lim HJ, Park JS, Cho YJ, Lee SW, Yoon HI, Lee JH, Kim YS, Lee CT.

Int J Mol Med. 2012 Feb;29(2):218-24. doi: 10.3892/ijmm.2011.831. Epub 2011 Nov 7.


Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.

Kim DR, Park MY, Lee CS, Shim SH, Yoon HI, Lee JH, Sung MW, Kim YS, Lee CT.

Cancer Gene Ther. 2011 Jul;18(7):467-77. doi: 10.1038/cgt.2011.11. Epub 2011 Apr 1.


Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.

Zhu ZB, Lu B, Park M, Makhija SK, Numnum TM, Kendrick JE, Wang M, Tsuruta Y, Fisher P, Alvarez RD, Zhou F, Siegal GP, Wu H, Curiel DT.

Int J Oncol. 2008 Jun;32(6):1179-88.


In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.

Lee CT, Lee YJ, Kwon SY, Lee J, Kim KI, Park KH, Kang JH, Yoo CG, Kim YW, Han SK, Chung JK, Shim YS, Curiel DT, Carbone DP.

Cancer Res. 2006 Jan 1;66(1):372-7.


Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.

Shim SH, Lee CT, Hun Hah J, Lee JJ, Park SW, Heo DS, Sung MW.

Cancer Sci. 2010 Feb;101(2):482-7. doi: 10.1111/j.1349-7006.2009.01409.x. Epub 2009 Oct 20.


Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.

Oh JY, Park MY, Kim DR, Lee JH, Shim SH, Chung JH, Yoon HI, Lee JH, Sung MW, Kim YS, Lee CT.

Int J Mol Med. 2010 Mar;25(3):369-76.


Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.

Lee CT, Park KH, Yanagisawa K, Adachi Y, Ohm JE, Nadaf S, Dikov MM, Curiel DT, Carbone DP.

Cancer Res. 2004 Sep 15;64(18):6660-5.


Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells.

Iguchi K, Sakurai F, Tomita K, Katayama K, Yamaguchi T, Kawabata K, Tagawa M, Kawabata M, Shirakawa T, Mizuguchi H.

Cancer Gene Ther. 2012 Feb;19(2):118-25. doi: 10.1038/cgt.2011.74. Epub 2011 Nov 11.


Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R.

Mol Cancer Ther. 2007 Jan;6(1):70-81.


A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.

Zhang B, Liu Y, Zhang P, Wei Y, Yin X, Zheng J.

Int J Gynecol Cancer. 2011 Dec;21(9):1540-6. doi: 10.1097/IGC.0b013e31823105ed.


Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.

Höti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R.

Mol Ther. 2006 Dec;14(6):768-78. Epub 2006 Sep 20.


A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.

Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.

PLoS One. 2010 Sep 14;5(9):e12417. doi: 10.1371/journal.pone.0012417.


Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.

Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, Fujiwara T.

Exp Cell Res. 2006 Feb 1;312(3):256-65. Epub 2005 Dec 13.


Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.

Oosterhoff D, Pinedo HM, Witlox MA, Carette JE, Gerritsen WR, van Beusechem VW.

Gene Ther. 2005 Jun;12(12):1011-8.


E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.

He XP, Su CQ, Wang XH, Pan X, Tu ZX, Gong YF, Gao J, Liao Z, Jin J, Wu HY, Man XH, Li ZS.

Cancer Lett. 2009 Nov 18;285(1):89-98. doi: 10.1016/j.canlet.2009.05.006. Epub 2009 May 28.


A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.

Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.

Cancer Gene Ther. 2008 Mar;15(3):173-82. Epub 2007 Dec 21.


Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.


P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.

Hsieh YJ, Hwu L, Chen YC, Ke CC, Chen FD, Wang HE, Lin KP, Yeh HH, Chang CW, Liu RS.

J Nucl Med. 2014 Apr;55(4):678-85. doi: 10.2967/jnumed.113.126573. Epub 2014 Mar 17.


5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.

He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, Li L, Wu H, Liu X, Wu M, Qian Q.

Hum Gene Ther. 2011 Mar;22(3):283-92. doi: 10.1089/hum.2010.058. Epub 2011 Jan 11.


Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.

Ji X, Zhang J, Cheng L, Wei F, Li H, Liu X, Chen X, Li C, Wang Y, Huang Q.

Exp Eye Res. 2009 Aug;89(2):193-9. doi: 10.1016/j.exer.2009.03.007. Epub 2009 Mar 27.

Items per page

Supplemental Content

Write to the Help Desk